Please assess the completion status of the following clinical trial:

Trial Title: APE-Study: Ablation of Barrett's Mucosa vs. Surveillance Without Ablation in Patients Cured From Barrett's Cancer Combined With Randomization of Esomeprazole vs. Placebo for Symptomatic Reflux Control After Successful Barrett's Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Endoscopically and histologically complete remission of mucosal Barrett's cancer (endoscopic resection with or without thermal ablation of resection margins)~* Initial length of Barrett's segment before cancer therapy \> 3 cm (initially long-segment Barrett's esophagus)~* Barrett's length after endoscopic therapy of Barrett's cancer \> 2 cm~* Informed consent of the patient~Exclusion Criteria:~* Attempted ablation therapy before the trial~* Treatment duration of early Barrett's cancer \> 12 months~* Duration between achievement of complete remission and attempted inclusion into the study \> 24 months~* The Barrett's cancer treated has already been a secondary lesion of earlier Barrett's cancer~* Inadequate healing of endoscopic resection (ER) ulcers~* No residual Barrett's mucosa observed after pretreatment with ER~* No PPI compliance~* Relevant comorbidity (e.g., malignancy)~* Pregnancy~* Age below 18 years~* Patient not able to understand study characteristics~* No written informed consent available~* Allergy against esomeprazole or intolerance of medication ingredients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ablation of Barretts with concomitant esomeprazole therapy (Type: OTHER): comparison of recurrence-free survival
- non ablation (Type: NO_INTERVENTION): non ablation only surveillance

Based on this trial design, predict the completion outcome and termination type (if applicable).